Is MDAI a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on FDA clearance opens the U.S. market, with revenue (ttm, mostly research/barda) at ~$15.4 million; FY2025 was ~$19.7 million. The bear case rests on the risks are substantial and concentrated. Analysts covering it are spread from $4.00 to $6.25, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The risks are substantial and concentrated. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $4.00, +164.9% from the $1.51 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

FDA clearance opens the U.S. market. In May 2026 Spectral AI received FDA De Novo clearance for the DeepView System's burn indication, the regulatory milestone the company had worked toward for years. The most optimistic analyst target on MDAI is $6.25, +313.9% from the $1.51 price. That figure is only reachable if this thesis works close to its best case.

The risks are substantial and concentrated. Even with De Novo clearance, commercialization risk is high: Spectral AI has almost no track record of selling product, and revenue, hospital adoption, and reimbursement for a novel AI imaging device are all unproven. The company depends heavily on government funding, so changes to BARDA or DoD contracts could sharply reduce the revenue it reports today. It is unprofitable and burns cash, with about $14.0 million of cash at June 30, 2026 against roughly $16.3 million of debt and a trailing net loss near $10.1 million, which makes further dilution through equity, warrants (MDAIW), or debt likely. As a micro-cap with roughly 32 million shares and a market value near $49 million as of October 16, 2026, the stock is thinly traded and highly volatile, and it faces competition from other wound-imaging and AI-diagnostics approaches as well as the inertia of standard visual assessment. The shares are down about 38% over the past year despite the FDA clearance, a sign that the market is waiting for first sales rather than paying for the milestone. The most pessimistic published target is $4.00, +164.9% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Medical-AI company whose DeepView System uses multispectral imaging and AI to predict burn and wound healing potential, pre-commercial and funded largely by BARDA and DoD contracts.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (FDA clearance opens the U.S. market) stalling in the reported numbers rather than in the narrative, the risk above (the risks are substantial and concentrated) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

Spectral AI is a medical-technology company whose DeepView System uses multispectral imaging and a proprietary AI algorithm to assess the healing potential of burns and wounds. It produces an objective, non-contact tissue classification in roughly 20 to 25 seconds, intended to help clinicians in burn centers, trauma centers, and emergency departments decide which tissue will heal on its own and which needs surgery. The company has been funded largely by U.S. government research contracts.

DeepView is Spectral AI's flagship system. It captures a sub-second multispectral image of a wound and runs a deep-learning algorithm, trained on a large proprietary database of clinically labeled burn images, to predict healing potential without touching the patient. The output aims to replace subjective visual judgment of burn depth with an objective, AI-driven read. A handheld Snapshot version is also in development with U.S. Department of Defense funding.

Spectral AI submitted a De Novo application to the FDA in June 2025 and received FDA De Novo clearance for the DeepView System's burn indication in May 2026, authorizing U.S. commercial distribution. Its development has been funded largely by government contracts, around $282.5 million awarded since 2013, mostly from BARDA under a Project BioShield contract, plus DoD support. That funding is booked as research revenue, so most of the company's reported revenue has come from grants rather than product sales. In October 2026 it filed for a Medicare New Technology Add-On Payment and began a study to expand the label to burns of the head, hands, and feet.